Literature DB >> 11707077

Characterization of the gene EPAC2: structure, chromosomal localization, tissue expression, and identification of the liver-specific isoform.

H Ueno1, T Shibasaki, T Iwanaga, K Takahashi, Y Yokoyama, L M Liu, N Yokoi, N Ozaki, S Matsukura, H Yano, S Seino.   

Abstract

The liver-specific protein cAMP-GEFII (also known as Epac2) belongs to a family of cyclic adenosine monophosphate (cAMP) binding proteins having guanine nucleotide exchange factor (GEF) activity (the cAMP-GEF family). Here we clone the gene EPAC2, encoding cAMP-GEFII, from a human liver cDNA library. Human EPAC2 has at least 31 exons and is mapped to human chromosome 2q31. Analyses by primer extension, reverse transcriptase-polymerase chain reaction, and in situ hybridization revealed the presence of three transcription start sites of liver-specific Epac2: two major sites located in exon 10 and a minor site in intron 9. The same translation start site is used in all three transcripts. Liver-specific cAMP-GEFII protein, which lacks the first cAMP-binding domain and the Dishevelled/Egl-10/Pleckstrin domain, was detected at 79 kDa by immunoblot analysis, confirming the presence of the short form of cAMP-GEFII in the liver. Liver-specific cAMP-GEFII also has GEF activity toward Rap1. These results demonstrate the presence of liver-specific cAMP-GEFII. Together with the previous finding that cAMP-GEFII is responsible for cAMP-dependent exocytosis in secretory cells, our study suggests that cAMP-GEFII may have a distinct role in liver.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707077     DOI: 10.1006/geno.2001.6641

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  23 in total

Review 1.  Cell physiology of cAMP sensor Epac.

Authors:  George G Holz; Guoxin Kang; Mark Harbeck; Michael W Roe; Oleg G Chepurny
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

2.  Suppressor of cytokine signaling-3 is a glucagon-inducible inhibitor of PKA activity and gluconeogenic gene expression in hepatocytes.

Authors:  Allison M Gaudy; Alicia H Clementi; Jean S Campbell; Alan V Smrcka; Robert A Mooney
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

3.  Structure-Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N'-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists.

Authors:  Na Ye; Yingmin Zhu; Haijun Chen; Zhiqing Liu; Fang C Mei; Christopher Wild; Haiying Chen; Xiaodong Cheng; Jia Zhou
Journal:  J Med Chem       Date:  2015-07-16       Impact factor: 7.446

4.  Activation of a cyclic amp-guanine exchange factor in hepatocytes decreases nitric oxide synthase expression.

Authors:  Baochun Zhang; Ikenna Nweze; Jaganathan Lakshmanan; Brian G Harbrecht
Journal:  Shock       Date:  2013-01       Impact factor: 3.454

5.  Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.

Authors:  Stefano Spolitu; Haruka Okamoto; Wen Dai; John A Zadroga; Erika S Wittchen; Jesper Gromada; Lale Ozcan
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 6.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 7.  Recent advances in the discovery of small molecules targeting exchange proteins directly activated by cAMP (EPAC).

Authors:  Haijun Chen; Christopher Wild; Xiaobin Zhou; Na Ye; Xiaodong Cheng; Jia Zhou
Journal:  J Med Chem       Date:  2013-11-27       Impact factor: 7.446

Review 8.  Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea.

Authors:  S Seino
Journal:  Diabetologia       Date:  2012-05-04       Impact factor: 10.122

Review 9.  The role of Epac in the heart.

Authors:  Takayuki Fujita; Masanari Umemura; Utako Yokoyama; Satoshi Okumura; Yoshihiro Ishikawa
Journal:  Cell Mol Life Sci       Date:  2016-08-22       Impact factor: 9.261

10.  The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).

Authors:  Jesús M Banales; Tatyana V Masyuk; Sergio A Gradilone; Anatoliy I Masyuk; Juan F Medina; Nicholas F LaRusso
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.